Lantheus Holdings (LNTH) Other Non-Current Liabilities (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Other Non-Current Liabilities of $49.9 million for Q1 2026, up 166.22% year-over-year from $18.7 million in Q1 2025, and down 53.75% quarter-over-quarter from $107.9 million in Q4 2025.
Lantheus Holdings (LNTH) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Other Non-Current Liabilities for 13 consecutive years, with $49.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 166.22% year-over-year to $49.9 million; the TTM figure through Mar 2026 stood at $49.9 million (up 166.22% YoY), while the FY2025 annual figure was $107.9 million, up 979.2% from the prior year.
- Other Non-Current Liabilities eased to $49.9 million in Q1 2026 per LNTH's latest filing, from $107.9 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $107.9 million in Q4 2025 and bottomed at $136000.0 in Q2 2025.
- Historically, Other Non-Current Liabilities has averaged $32.3 million across 5 years, with a median of $22.9 million in 2023.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 979.2% in 2025 and fell as far as 99.46% in 2025.
- Lantheus Holdings' Other Non-Current Liabilities stood at $22.5 million in 2022, then gained by 1.65% to $22.9 million in 2023, then sank by 56.38% to $10.0 million in 2024, then jumped by 979.2% to $107.9 million in 2025, then plunged by 53.75% to $49.9 million in 2026.
- Business Quant data shows LNTH's Other Non-Current Liabilities at $49.9 million in Q1 2026, $107.9 million in Q4 2025, and $137000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.53 Mn |
| Mar 31, 2026 | 49.89 Mn |
| Dec 31, 2025 | 107.87 Mn |
| Sep 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 18.74 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 23.24 Mn |
| Jun 30, 2024 | 25.10 Mn |
| Mar 31, 2024 | 63.11 Mn |
| Dec 31, 2023 | 22.92 Mn |
| Sep 30, 2023 | 62.85 Mn |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 22.64 Mn |
| Dec 31, 2022 | 22.54 Mn |
| Sep 30, 2022 | 46.49 Mn |
| Jun 30, 2022 | 49.62 Mn |
| Mar 31, 2022 | 21.51 Mn |
| Dec 31, 2021 | 20.83 Mn |
| Sep 30, 2021 | 89.64 Mn |